Factors Influencing Imatinib-Induced Hepatotoxicity
활용도 Analysis
논문 Analysis
연구자 Analysis
저자
한지민
이정
조윤숙
곽혜선
제어번호
106509077
학술지명
Cancer Research and Treatment
권호사항
Vol.
52
No.
1
[
2020
]
발행처
대한암학회
발행처 URL
http://www.cancer.or.kr
자료유형
학술저널
수록면
181-188
언어
English
출판년도
2020
등재정보
KCI등재
소장기관
경북대학교 도서관 의학분관
부산대학교 중앙도서관
판매처
'
Factors Influencing Imatinib-Induced Hepatotoxicity' 의 참고문헌
hOCT 1 and resistance to imatinib
Very important pharmacogene summary : ABCB1(MDR1, P-glycoprotein)
Specific targeted therapy of chronic myelogenous leukemia with imatinib
Recent status of drug-induced liver injury and its problem in japan
Proton pump inhibitors in cirrhosis : tradition or evidence based practice
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase : S0033
Pharmacokinetic resistance to imatinib mesylate : role of the ABC drug pumps ABCG2(BCRP)and ABCB1(MDR1)in the oral bioavailability of imatinib
Pharmacokinetic interaction between ketoconazole and imatinib mesylate(Glivec)in healthy subjects
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib(AMN107) : reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib
Indications for imatinib mesylate therapy and clinical management
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia : a subanalysis of the IRIS study
Imatinib mesylate(gleevec)hepatotoxicity
Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Highlights of prescribing information: Gleevec (imatinib mesylate)
Hepatotoxicity of tyrosine kinase inhibitors : clinical and regulatory perspectives
Effects of concomitant medication use on gefitinib-induced hepatotoxicity
Effect of rifampicin on the pharmacokinetics of imatinib mesylate(Gleevec, STI571)in healthy subjects
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Drug absorption interactions between oral targeted anticancer agents and PPIs : is pH-dependent solubility the Achilles heel of targeted therapy
Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1(hOCT1; SLC22A1), hOCT2(SLC22A2), and hOCT3(SLC22A3)
Clinical pharmacokinetics of imatinib
Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
Approval summary : imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour : a randomised, double-blind, placebo-controlled trial
Active transport of imatinib into and out of cells : implications for drug resistance
ABC multidrug transporters : structure, function and role in chemoresistance
'
Factors Influencing Imatinib-Induced Hepatotoxicity'
의 유사주제(
) 논문